INS and type 1 diabetes mellitus: In contrast, nanocarrier platforms (Table 3) have shown encouraging early results but ultimately encountered challenges that limited their progress: Diasome’s hepatocyte-directed vesicle (HDV) technology, a lipid nanoparticle additive designed to target insulin to hepatocytes, advanced into multiple Phase II studies in type 1 diabetes.